Concise drug review: Pazopanib and axitinib

Oncologist

Volumn 17, Issue 8, 2012, Pages 1081-1089

  van Geel, Robin M J M ^a   Beijnen, Jos H ^b,c   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Angiogenesis; Axitinib; Drug profile; Pazopanib; VEGF

Indexed keywords

AXITINIB; CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DYSPHONIA; DYSPNEA; FATIGUE; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; KIDNEY METASTASIS; LEUKOPENIA; LIVER DISEASE; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; ONCOGENE C KIT; OVERALL SURVIVAL; PATIENT EDUCATION; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; META-ANALYSIS AS TOPIC; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865253075     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0055     Document Type: Review

References (47)

1. Bukowski RM, Yasothan U. Kirkpatrick P. Pazopanib. Nat Rev Drug Discov 2010;9:17-18.
2. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28:1061-1068.
3. Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol 2009;27:3126-3132.
4. Friedlander M, Hancock KC, Rischin D et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119:32-37.
5. Altorki N, Lane ME, Bauer T et al. Phase II proofof-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-smallcell lung cancer. J Clin Oncol 2010;28:3131-3137.
6. Bible KC, Suman VJ, Molina JR et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010;11:962-972.
7. U.S. Food and Drug Administration (FDA). FDA Briefing Document, Oncologic Drugs Advisory Committee Meeting, NDA 202324 Axitinib (Inlyta_). Silver Spring, MD: FDA, 2011.
8. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011;378:1931-1939.
9. ClinicalTrials. gov. Available at http://www.clinicaltrials. gov, accessed April 24, 2012.
10. Glade Bender JL, Lee A, Adamson PC et al. Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium. J Clin Oncol 2011; 29(suppl):9501.
11. Hutson TE, Davis ID, Machiels JP et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28:475-480.
12. Bukowski RM. Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res 2011;3:273-285.
13. Rini BI, Wilding G, HudesGet al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-4468.
14. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007;8:975-984.
15. Motzer RJ, de La Motte Rouge T, Harzstark AL et al. Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. J Clin Oncol 2011;29(suppl):4547.
16. Votrient (pazopanib) tablets [full prescribing information]. Brentford, U.K.: GlaxoSmithKline, 2009.
17. Inlyta (axitinib) tablets [full prescribing information]. New York: Pfizer, 2012.
18. Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. The Oncologist 2010;15: 539-547.
19. European Medicines Agency. Votrient (Pazopanib): Summary of Product Characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/001141/ WC500094272.pdf, accessed April 29, 2012.
20. Sonpavde G, Hutson TE. Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007;9:115-119.
21. Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. The Oncologist 2010;15:436-446.
22. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: Current status. Curr Oncol Rep 2011;13:103-111.
23. Sparidans RW, Iusuf D, Schinkel AH et al. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:4090-4096.
24. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009;15:4220-4227.
25. Yau T, Chen PJ, Chan P et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 2011;17:6914-6923.
26. Heath EI, Chiorean EG, Sweeney CJ et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther 2010;88:818-823.
27. Heath EI, Forman K, Malburg L et al. A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs 2011 Aug 3 [Epub ahead of print].
28. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-5483.
29. Pithavala YK, Tong W, Mount J et al. Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 2012;30:273-281.
30. Pithavala YK, Tortorici M, Toh M et al. Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010;65:563-570.
31. Kelly RJ, Rixe O. Axitinib (AG-013736). In: Martens UM. Small Molecules in Oncology. Berlin, Germany: Springer, 2010:33-44.
32. Tortorici MA, Toh M, Rahavanedran SV et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs 2011;29: 1370-1380.
33. Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Australian Public Assessment Report for Pazopanib Hydrochloride. Available at http://www.tga.gov.au/pdf/auspar/ausparvotrient. pdf, accessed April 29, 2012.
34. Spano JP, Moore MJ, Pithavala YK et al. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs 2011 Jun 14 [Epub ahead of print].
35. Monk BJ, Mas Lopez L, Zarba JJ et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 2010;28:3562-3569.
36. Tan AR, Dowlati A, Jones SF et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. The Oncologist 2010;15:1253-1261.
37. Shibata S, Longmate J, Chung VM et al. A phase I and pharmacokinetic single agent study of pazopanib (P) in patients (Pts) with advanced malignancies and varying degrees of liver dysfunction (LD). J Clin Oncol 2010; 28(15 suppl):2571.
38. Brennan M, Williams JA, ChenYet al. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol 2012;68:645-655.
39. Xu CF, Bing NX, BallHAet al. Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 2011;29:2557-2564.
40. Gril B, Palmieri D, Qian Y et al. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS One 2011;6:e25625.
41. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010;1:12-25.
42. Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A 2002;99:4349:4354.
43. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-2621.
44. Liu G, Rugo HS, Wilding G et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J Clin Oncol 2005;23:5464-5473.
45. Rini BI, Schiller JH, Fruehauf JP et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17:3841-3849.
46. Suttle B, Ball HA, Molimard M et al. Relationship between exposure to pazopanib (P) and efficacy in patients (pts) with advanced renal cell carcinoma (mRCC). J Clin Oncol 2010;28(15 suppl):3048.
47. Hutson TE, Davis ID, Machiels JH et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008;26(suppl):5046.